Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity (BEAT-ROP)

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2008
The purpose of this study was to determine the efficacy and additional advantages of intravitreal bevacizumab in the treatment of ROP for both Zone I and Zone II Posterior.
Epistemonikos ID: bcc11fef632476832d6b0b70c668a4e3d2b55873
First added on: Oct 05, 2018